Gain Therapeutics Q2 net loss $0.42/shr; expects MAD Phase 1 topline for GT-02287 in August 2024

Gain Therapeutics, Inc.

2024-Q2 EPS reported -$0.65

Net loss per share $0.42 for Q2 2024 vs $0.62 in Q2 2023; cash & securities $16.9M as of June 30, 2024.
Topline results from MAD Phase 1 study of GT-02287 for Parkinson's disease expected in August 2024.
Phase 1b study in Parkinson's patients with/without GBA1 mutation initiation anticipated in Q4 2024.
Gene Mack appointed interim CEO and CFO; Khalid Islam serves as Executive Chairman.
Completed underwritten public offering with approximately $10.0M net proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.